Literature DB >> 32461206

A pilot study of tofacitinib for refractory Behçet's syndrome.

Jinjing Liu1,2, Yunxia Hou3, Luxi Sun1,2, Chaoran Li1,2, Lu Li1,2, Yan Zhao1,2, Xiaofeng Zeng1,2, Fengchun Zhang1,2, Wenjie Zheng4,2.   

Abstract

Entities:  

Keywords:  Behcet's disease; DMARDs (synthetic); treatment

Mesh：

Substances：

Year:  2020        PMID： 32461206     DOI： 10.1136/annrheumdis-2020-217307

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  16 in total

1.  JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides.

Authors:  Sujoy Khan
Journal:  Clin Med (Lond)       Date:  2021-03       Impact factor: 2.659

2.  Single-cell analyses highlight the proinflammatory contribution of C1q-high monocytes to Behçet's disease.

Authors:  Wenjie Zheng; Xiaoman Wang; Jinjing Liu; Xin Yu; Lu Li; Heping Wang; Jijun Yu; Xiaoya Pei; Chaoran Li; Zhimian Wang; Menghao Zhang; Xiaofeng Zeng; Fengchun Zhang; Chenfei Wang; Hua Chen; Hou-Zao Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-21       Impact factor: 12.779

Review 3.  Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease.

Authors:  Nina Couette; Wael Jarjour; Jonathan E Brammer; Alexa Simon Meara
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

4.  Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review.

Authors:  Zhivana Boyadzhieva; Nikolas Ruffer; Gerd Burmester; Anne Pankow; Martin Krusche
Journal:  Front Med (Lausanne)       Date:  2022-06-27

Review 5.  Advances in the Treatment of Behcet's Disease.

Authors:  Fatma Alibaz-Oner; Haner Direskeneli
Journal:  Curr Rheumatol Rep       Date:  2021-05-20       Impact factor: 4.592

Review 6.  A Contemporary Review of Behcet's Syndrome.

Authors:  Jingjing Chen; Xu Yao
Journal:  Clin Rev Allergy Immunol       Date:  2021-06-02       Impact factor: 8.667

7.  Genetic Association of a Gain-of-Function IFNGR1 Polymorphism and the Intergenic Region LNCAROD/DKK1 With Behçet's Disease.

Authors:  Lourdes Ortiz Fernández; Patrick Coit; Vuslat Yilmaz; Sibel P Yentür; Fatma Alibaz-Oner; Kenan Aksu; Eren Erken; Nursen Düzgün; Gokhan Keser; Ayse Cefle; Ayten Yazici; Andac Ergen; Erkan Alpsoy; Carlo Salvarani; Bruno Casali; Bünyamin Kısacık; Ina Kötter; Jörg Henes; Muhammet Çınar; Arne Schaefer; Rahime M Nohutcu; Alexandra Zhernakova; Cisca Wijmenga; Fujio Takeuchi; Shinji Harihara; Toshikatsu Kaburaki; Meriam Messedi; Yeong-Wook Song; Timuçin Kaşifoğlu; F David Carmona; Joel M Guthridge; Judith A James; Javier Martin; María Francisca González Escribano; Güher Saruhan-Direskeneli; Haner Direskeneli; Amr H Sawalha
Journal:  Arthritis Rheumatol       Date:  2021-05-18       Impact factor: 15.483

Review 8.  Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future.

Authors:  Roberto Bursi; Giacomo Cafaro; Carlo Perricone; Ilenia Riccucci; Santina Calvacchi; Roberto Gerli; Elena Bartoloni
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

Review 9.  Old and New Challenges in Uveitis Associated with Behçet's Disease.

Authors:  Julie Gueudry; Mathilde Leclercq; David Saadoun; Bahram Bodaghi
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

Review 10.  Recent Insights into the Management of Behçet Syndrome.

Authors:  Yesim Ozguler; Ayse Ozdede; Gulen Hatemi
Journal:  J Inflamm Res       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.